Trial document




drksid header

  DRKS00024798

Trial Description

start of 1:1-Block title

Title

CARNA Pretest - Pre-study to assess a medical benefit and positive care effects of an app-based, guideline-compliant patient support in heart failure.

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

CARNA Pretest

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

https://procarement.com/studie/

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

For patients with heart failure, regular monitoring of health status to adjust treatment and avoid complications is a critical component of care. Telemedicine interventions that facilitate such monitoring have already led to positive care effects in other trials. The ProHerz app is a software application that supports guideline-based care. In combination with wearables, vital parameters are collected and evaluated, and the user is given information about his or her health status to enable better management. In order to make this care approach the norm, the app is to be listed as a digital health application (DiGA). By means of a clinical trial, positive health care effects are to be proven in accordance with the Digital Health Care Act (DVG). To test the feasibility, this preliminary study precedes the clinical evaluation trial in cooperation with the Nuremberg Hospital.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The aim of the single-center, national, exploratory trial is to investigate how an evaluation trail on the use of the ProHeart App can be conducted for a positive care effect according to the Digital Care Act (DVG) for patients with heart failure. The ProHerz App is a software application that supports guideline-based care.
It will be examined whether the selected measurement instruments of the study (such as standardised gait tests, patient questionnaires) provide indications of the care effects. In addition, it will be examined whether the study design can be implemented for an evaluation trial with regard to recruitment, data collection, drop-out rate and sample size. In addition, the usability of the ProHerz app will be evaluated.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

No

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00024798
  •   2021/04/30
  •   [---]*
  •   no
  •   Approved
  •   21022, Ethik-Kommission der Bayerischen Landesärztekammer
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   I50 -  Heart failure
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Access to the ProHerz App, for 3 months
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Supportive care
  •   Single (group)
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

▪ Change in the 6-minute walk test
▪ Change in EQ-5D-L Index
▪ Change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Index
▪ Change in the 9-item European Heart Failure Self-care Behaviour Scale (G9-EHFScBS)
▪ Change in 9-item Shared Decision Making Questionnaire (SDM-Q-9) score.
▪ Change in Atlanta Heart Failure Knowledge Test (AHFKT) score.
▪ Change in the NYHA classification
▪ Self-reported utalisation of outpatient and inpatient health care services
▪ Intensity of the use of the ProHerz app over the observation period
▪Survey of the usability of the ProHerz app with the System Usability Score (SUS), the manufacturer's own questions and an interview of max. 30 minutes.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

-

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2021/04/30
  •   100
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

▪ Diagnosed heart failure (ICD code I 50 ff)
▪ Age > 18 years
▪ Ability to speak and read in German
▪ Ability to use an application running on a smartphone or other mobile device
▪ Informed consent of the study participant

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

▪ No possession of a smartphone or mobile device with internet access.
▪ Cognitive impairment with the inability to give consent to the protocol.
▪ Inability or unwillingness to use an app (e.g. dementia, blindness, deafness, wheelchair use, insufficient German language skills, limited informal self-determination)
▪ Hospitalisation within the last 7 days
▪ Condition after implantation of a mechanical cardiac assist system
▪ Acute coronary syndrome within the last 7 days
▪ high urgent HTX listing
▪ Planned revascularisation, TAVI; mitral clip, etc.
▪ CRT implantation within the last 3 months
▪ Revascularisation and/or CRT implantation within the last 3 months
▪ Chronic drug or alcohol abuse according to the doctor's assessment
▪ Terminal renal failure with haemodialysis treatment (ICD code N18.5)
▪ Diseases with a life expectancy < 12 months
▪ Pregnancy
▪ Participation in other therapy studies or other telemedicine programmes
▪ Indication of corona disease

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • ProCarement GmbH
    • Ms.  Patricia  Trißler 
    • Äußere Nürnberger Str. 62
    • 91301  Forchheim
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address other
    • ZEW-Leibniz-Zentrum für Europäische Wirtschaftsforschung GmbH
    • Mr.  Dr.  Simon  Reif 
    • L 7,1
    • 68161  Mannheim
    • Germany
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    end of 1:1-Block address contact other
  • start of 1:1-Block address scientific-contact
    • dmac- Medical Valley Digital Health Application Center GmbH
    • Ms.  Sophie  Terheyden 
    • Promenadestr. 6a
    • 96047  Bamberg
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • ProCarement GmbH
    • Mr.  Dr. med.  Sebastian  Eckl 
    • Äußere Nürnberger Str. 62
    • 91301  Forchheim
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • ProCarement GmbH
    • Ms.  Patricia  Trißler 
    • Äußere Nürnberger Str. 62
    • 91301  Forchheim
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up continuing
  •   [---]*
  •   [---]*
  •   [---]*
  •   71
  •   71
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.